Cancer antigen 19-9 (CA 19-9)

Included in meta analysis


Erden G, Barazi AO, Tezcan G and Yildirimkaya MM, 2008, Scand J Clin Lab Invest, 68, 212-8 , Biological variation and reference change vàlues of CA 19-9, CEA, AFP in sèrum of healthy individuals


Total Score


Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis B
7. Steady State B
8. Outlier Analysis C
9. Normality A
10. Variance Homogeneity C
12. CI A
13. No of Results B
14. Concentrations A
15. Total Score C8,10

Item Details

Parameter Score
Matrix Serum
Measurand Cancer antigen 19-9 (CA 19-9)
Unit U / mL
Overall Analytical Principle Method Immunoassay; RIA
Number of Subjects 49
Number of Subjects included in BV estimation 38
Ethinicity Unknown
Age Mean / Median 33.0
Age Min 18.0
Age Max 60.0
Age SD
Number of Males 25
Number of Females 24
State of Well Being
Healthy (excl pregnant)
Study Duration Length 6
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 14
Interval Units Day
Sampling Times Start Time: 08:00
End Time: 10:00
Number of Samples 4
Average Number of Samples Used for BV Estimation 4.0
Average Number of Replicates 2.0
Estimates of CVi 27.2
Calculated Confidence Intervals of CVi Lower: 24.01, Upper: 31.33
Estimates of CVg 64.24
Calculated Confidence Intervals of CVg Lower: 51.88, Upper: 83.53
Analytical CV 5.39
Calculated Confidence Intervals of Analytical CV Lower: 4.85, Upper: 6.07
Measurand Mean 5.098
Measurand Min 1.9
Measurand Max 12.253
Measurand SD 3.147